HEPLISAV-B Exposure in Pregnant Women and Their Offspring
Study Description
“DV2-HBV-27: Observational Pregnancy Registry”
Purpose of the study is to evaluate pregnancy outcomes among women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy
Location
Methods
No pharmaceutical medication involved
Patients and healthy individuals accepted
Biological - HEPLISAV-B
This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
Additional Information
Official Study Title
HEPLISAV-B Pregnancy Registry: An Observational Study on the Safety of HEPLISAV-B Exposure in Pregnant Women and Their Offspring
Clinical Trial ID
NCT03664648
ParticipAid ID
dBBrNd
